semaglutide ckd trial Effects of on Body Composition and GFR : Clinical Journal of the American Society of Nephrology Semaglutides Are Poised to Remake

However, as noted previously by Zweck et al

These results provided us with the essential methodology to design the GLP-1 infusion study and provided information on the estimated number of participants needed for adequate statistical power

GLP-1 receptor agonists may be considered for their FDA-approved indications glycemic control in type 2 diabetes or chronic weight management in obesitybut should not be viewed as treatments for Hashimoto's disease itself

But "not FDA-approved" doesn't mean "inaccessible." There are legitimate pathways available right now, and there's a lot to understand about what this drug actually does before you decide whether to wait or act